T. Rowe Price Associates’s Trevi Therapeutics TRVI Stock Holding History

T. Rowe Price Associates’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$772K	Buy	64,703 +14,430	+29%	+$162K	﹤0.01%	2264
2025 Q4	$630K	Buy	50,273 +3,414	+7%	+$39.5K	﹤0.01%	2289
2025 Q3	$429K	Buy	46,859 +8,307	+22%	+$62.3K	﹤0.01%	2428
2025 Q2	$211K	Buy	38,552 +6,390	+20%	+$39.8K	﹤0.01%	2691
2025 Q1	$203K	Buy	32,162 +6,996	+28%	+$33.4K	﹤0.01%	2632
2024 Q4	$104K	Buy	25,166 +6,119	+32%	+$19.6K	﹤0.01%	2827
2024 Q3	$64K	Hold	19,047	–	–	﹤0.01%	2897
2024 Q2	$57K	Buy	19,047 +5,486	+40%	+$15.2K	﹤0.01%	2839
2024 Q1	$47K	Buy	+13,561	New	+$30.3K	﹤0.01%	2880

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

T. Rowe Price Associates's TRVI Position: Q1 2026 in Review

T. Rowe Price Associates increased its Trevi Therapeutics (TRVI) stake by 29% in Q1 2026, buying an estimated $162K and bringing the position to 64,703 shares worth $772K. The position accounts for ﹤0.01% of the portfolio, ranked #2264.

T. Rowe Price Associates first reported a position in TRVI in Q1 2024 and has held it in 9 quarters since. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

T. Rowe Price Associates held 64,703 shares of Trevi Therapeutics worth $772K as of Q1 2026.
T. Rowe Price Associates bought 14,430 Trevi Therapeutics shares in Q1 2026, an estimated $162K.
Trevi Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2264 holding.
T. Rowe Price Associates first reported a position in Trevi Therapeutics in Q1 2024 and has held it in 9 quarters since.
198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.